Table 1.
Baseline patient and disease characteristics
| Characteristics | Frequency distribution, n (%), or median (IQR)† | P value | ||
|---|---|---|---|---|
| Overall (N = 93) | Malaysia (n = 39) | Thailand (n = 54) | ||
| At initial diagnosis | ||||
| Age (y)† | 67 (61.5‐74) | 66 (62‐69) | 67.5 (60.8‐76) | .060 |
| PSA (ng/mL)† | 101 (30‐347) | 223 (61.6‐1717) | 76.7 (22.8‐238) | .005 |
| *unknown | 10 | 8 | 2 | |
| Gleason score | ||||
| ≤6 | 15 (17.4) | 6 (18.2) | 9 (17.0) | .098 |
| 7 | 24 (27.9) | 8 (24.2) | 16 (30.2) | |
| ≥8 | 47 (54.7) | 19 (57.6) | 28 (52.8) | |
| *unknown | 7 | 6 | 1 | |
| Presence of metastases (M1) at initial diagnosis of prostate cancer | ||||
| No | 22 (24.7) | 9 (25.7) | 13 (24.1) | .861 |
| Yes | 67 (75.3) | 26 (74.3) | 41 (75.9) | |
| *unknown | 4 | 4 | 0 | |
| Prior therapy | ||||
| Primary local treatment | ||||
| Radical prostatectomy | 4 (4.3) | 0 | 4 (7.4) | <.001 |
| Radiotherapy | 11 (11.8) | 10 (25.6) | 1 (1.9) | |
| None | 78 (83.9) | 29 (74.4) | 49 (90.7) | |
| Primary ADT | ||||
| LHRH agonist | 56 (60.2) | 27 (69.2) | 29 (53.7) | .017 |
| LHRH antagonist | 9 (30.1) | 0 | 9 (29.6) | |
| Orchidectomy | 28 (9.7) | 12 (30.8) | 16 (16.7) | |
| Duration of primary ADT | 30.3 (15.3‐55.9) | 31.4 (14.6‐61.7) | 28.9 (15.4‐51.4) | .559 |
| *unknown | 3 | 3 | 0 | |
| PSA doubling time (mo)† | 2.4 (1.5‐4.2) | 2 (1.4‐3.1) | 2.4 (1.5‐5.1) | .417 |
| *unknown | 4 | 2 | 2 | |
| Time from ADT to mCRPC (mo)† | 21 (9.5‐47.5) | 21.1 (9‐48.5) | 19.8 (11.4‐47.4) | .762 |
| *unknown | 4 | 4 | 0 | |
| Chemotherapy status | ||||
| Chemo‐naïve | 69 (74.2) | 28 (71.8) | 41 (75.9) | .653 |
| Post‐chemo | 24 (25.8) | 11 (28.2) | 13 (24.1) | |
| At abiraterone initiation | ||||
| Age (y)† | 70 (65‐78) | 68 (65‐73) | 73 (65.8‐81) | .115 |
| PSA (ng/mL)† | 66.6 (20.6‐165.5) | 82.4 (33‐223) | 47.5 (12.5‐187.5) | .071 |
| *unknown | 2 | 0 | 2 | |
| ECOG status | ||||
| 0‐1 | 68 (76.4) | 29 (76.3) | 39 (76.5) | .059 |
| 2 | 15 (16.9) | 4 (10.5) | 11 (21.5) | |
| 3‐4 | 6 (6.7) | 5 (13.2) | 1 (2.0) | |
| *unknown | 4 | 1 | 3 | |
| Comorbidity count | ||||
| 0 | 36 (38.7) | 8 (20.5) | 28 (51.9) | .012 |
| 1 | 26 (28.0) | 14 (35.9) | 12 (22.2) | |
| 2 | 21 (22.5) | 10 (25.7) | 11 (20.3) | |
| ≥3 | 10 (10.8) | 7(17.9) | 3 (5.6) | |
| Year of initiation | ||||
| 2012‐2014 | 17 (18.3) | 11 (28.2) | 6 (11.1) | .027 |
| 2015 | 27 (29.0) | 10 (25.6) | 17 (31.5) | |
| 2016 | 28 (30.1) | 14 (35.9) | 14 (25.9) | |
| 2017 | 21 (22.6) | 4 (10.3) | 17 (31.5) | |
Abbreviations: ADT, androgen deprivation therapy; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; mCRPC, metastatic castrate‐resistant prostate cancer; PSA, prostate‐specific antigen.
†
Indicates that the value of these factors were stated in median (IQR).
Colour shaded values indicates statistical significant P‐values.